Commercial insurance delays direct‐acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients

Introduction The advent of direct‐acting antivirals (DAAs) has created an avenue for transplantation of hepatitis C virus (HCV)‐infected donors into uninfected recipients (D+/R−). The donor transmission of HCV is then countered by DAA administration during the post‐operative period. However, initiat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transplant infectious disease 2021-02, Vol.23 (1), p.e13449-n/a
Hauptverfasser:	Torabi, Julia, Rocca, Juan P., Ajaimy, Maria, Melvin, Jeffrey, Campbell, Alesa, Akalin, Enver, Liriano, Luz E., Azzi, Yorg, Pynadath, Cindy, Greenstein, Stuart M., Le, Marie, Goldstein, Doctor Y., Fox, Amy S., Carrero, Jin, Weiss, Jeffrey M., Powell, Tia, Racine, Andrew D., Reinus, John F., Kinkhabwala, Milan M., Graham, Jay A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents Demography Hepatitis Hepatitis C Insurance insurance authorization kidney transplant Kidney transplantation Kidney transplants Pharmacy benefit management Transplants & implants Viremia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!